Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGAV | P06756 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661557 | 0.82 | TP53 (0.40) | PPARAPPARGTP53 | |
| SCHEMBL5660891 | 0.81 | PPARA (0.41) | PPARAPPARGTP53 | |
| SCHEMBL5659447 | 0.81 | TP53 (0.40) | PPARAPPARGTP53 | |
| SCHEMBL14526519 | 0.74 | TP53 (0.42) | KMT2ATP53 | |
| SCHEMBL14526514 | 0.73 | TP53 (0.42) | KMT2ATP53 | |
| SCHEMBL14526521 | 0.73 | TP53 (0.42) | KMT2APPARATP53 | |
| SCHEMBL14526735 | 0.70 | TP53 (0.38) | KMT2APPARATP53 | |
| SCHEMBL14526723 | 0.70 | TP53 (0.40) | PPARAPPARGTP53 | |
| SCHEMBL14526699 | 0.69 | TP53 (0.38) | KMT2ATP53 | |
| SCHEMBL5661651 | 0.68 | PPARA (0.42) | KMT2APPARAPPARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | KMT2A 3018/4885PPARA 251/4885PPARG 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.